埃格列凈(Inn；商標名稱StigalTro)是一種治療2型糖尿病的藥物。在美國，它被食品和藥物管理局批準作為單一療法和固定劑量聯(lián)合使用西他列汀或二甲雙胍。在歐洲，它在2018年3月被批準用于單一療法或聯(lián)合療法。
2-Chloro-5-methylbenzoic acid
(S)-5-Oxopyrrolidine-2-carboxylic acid
(3aS,4S,6R,6aS)-6-((R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-ol
1-Methylpiperazine
(2S,3R,4S,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
N,O-Dimethylhydroxylamine hydrochloride
2,3,4,6-Tetra-O-benzyl-D-glucono-1,5-lactone
Ethoxybenzene
Iodomethyl pivalate
1,3-Propanedithiol
2,3,4,6-Tetra-O-(trimethylsilyl)-D-glucono-delta-lactone
4-Bromo-1-chloro-2-(4-ethoxybenzyl)benzene
(S)-5-Oxopyrrolidine-2-carboxylic acid compound with (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (1:1)
(2S,3R,4S,5S)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6,6-bis(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
(3AS,4S,6R,6aS)-6-((tert-butyldimethylsilyl)oxy)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbaldehyde
2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1,3-dithiane
2-((Benzyloxy)(4-ethoxyphenyl)methyl)-4-bromo-1-chlorobenzene
